Biochem Pharma (BCHE) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biochem Pharma (BCHE)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jim Oravetz who wrote (740)	4/28/2000 1:47:00 AM
From: Spekulatius	Read Replies (2) of 783

BCHE's solid quarter. My comments: - they beat earnings partly because dOTC development was on hold; the reason for the reduction in R &D costs from 20.3M$ to 16.7M$. The development cost will go up again with (-) dOTC development. + (-) dOTC development is a LT positive + Zeffix shows nice growth + LT Upside due to vaccine R&D deal + Divestments and genomics investments Overall a very solid quarter. Good work!

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next